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ABSTRACT 
 
The Development Speed Paradox - the observation that increasing development speed by reducing 
the cycle time of successful molecules INCREASES the expected time to first marketing authorization 
approval.  Conversely, building opportunities to fail unmarketable molecules earlier in the 
development process - fast-fail strategies - will shorten the time to first marketing authorization 
approval.  By focusing on the small minority of molecules that make it to market, development 
speed initiatives may sub-optimize the research and development process increasing costs and 
lowering productivity. 
 
 
 
  
More Haste, Less Speed 
 
Getting products to market in the shortest possible time has become an obsession within the 
industry.  And the arguments for accelerating development speed are compelling.  Cutting one 
month from the development life-cycle translates to an extra month of patent protected sales.  But 
while development speed is crucially important, an obsession with development speed to the 
exclusion of all else can run a company into the ground. 
 
"It is no good getting useless products to market quickly." 
Mike Emmanual, Director R&D, Janssen Pharmaceuticals UK 
 
One of the dangers of the current obsession is that maximizing development speed may actually 
increase the expected time to marketing authorization approval.  This is known as the Development 
Speed Paradox.  How does this arise? 
It is a sad fact that only 10% of compounds make it from man to market.  If you gear drug 
development to regulatory submission you optimize a process which will occur just 10% of the time.  
The remaining 90% of compounds will never get to new drug application submission.  Instead of 
maximizing development speed we need to "fast fail" these compounds to clear the pipeline for new 
candidates.  Any strategy which clears the pipeline of the 'no hopers' should be considered, even if it 
does so at the apparent expense of development speed.  Let's look at an example. 
A major pharmaceutical company debates the use of a service formulation to obtain early 
information on pharmacology in man together with preliminary safety data.  A heated debate 
ensues.  The “Right First Time” lobby argues that early studies in man with a service formulation will 
result in those early studies being re-worked, even repeated, for regulatory submission.  Why waste 
time on preliminary studies using a formulation you know will never cut it? 
However, the “Right First Time” lobby is missing the point.  These early studies yield valuable 
information of direct interest.  If in these early studies you find your candidate has no 
pharmacological effect or has serious safety problems then you are unlikely to submit to a regulatory 
agency.  So why worry about whether those studies could be submitted?  Why not build your 
development programme around early identification of the 90% that don’t make it rather than 
optimizing it around the 10% that will. 
Let’s compare the Right First Time (RFT) Strategy with the Fast Fail (FF) Strategy.  In the graphic 
below we have the two strategies.  
 
  
The RFT Strategy has a two year screening time followed by an eight year development time making 
10 years to take a compound to market.  The FF Strategy has a one year screening time with a 
service formulation followed by ten years of development making a total development time of 11 
years. 
Superficially it looks as though Right First Time Strategy with a total development time of just 10 
years is the better bet since it has the shortest overall development time – 10 years compared to 11 
years – a whole year shorter.  A whole year of additional patent-protected sales? 
 
However, using the simple model in the Box below we see that the expected time to market for the 
RFT Strategy is given by: 
ETTMRFT = (1/0.1)*2 + 8 
ETTMRFT = 28 years 
And the expected time to market for the Fast Fail Strategy is given by: 
ETTMFF = (1/0.1)*1 + 10 
ETTMFF = 20 years 
The expected time to the first marketing success using the Fast Fail Strategy is 8 years less than for 
Right First Time Strategy even though it has the longer overall development time.  
 
  
In fact, the Fast Fail Strategy outperforms the Right First Time Strategy for a range of probabilities - 
see Table 1. 
 
 
Not until the probability of success exceeds 50% and the majority of projects are likely to be 
successful does the Right First Time Strategy beat the Fast Fail Strategy.  But then, just how many 
companies can boast a 50% development success rate? 
 
 
 
 
 So why does the Fast Fail Strategy work so well? 
Well, the reason for this is that by clearing the pipeline and making way for new compounds to be 
evaluated there is a better chance of identifying a ‘good’ candidate that will make it all the way to 
market.  Of course, as the proportion of such ‘good’ candidates increases the advantages accruing 
from sweeping the pipeline decrease and there comes a point where the Right First Time strategy 
pays off. 
 
Pharmaceutical development is a business.  And we perform research to guide business decisions. 
Clearing the pipeline for further compounds to be evaluated requires senior management discipline.  
The will to kill has to be there.  The alternative is to clog the pipeline with ineffective medicines of 
marginal value for which there is no place in today’s world.  Strategies that clear those clogged 
pipelines are of greater value than those that speed marginal medicines to market. 
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SUMMARY 
 
The Development Speed Paradox - the observation that increasing development speed by reducing 
the cycle time of successful molecules INCREASES the expected time to first marketing authorization 
approval.  Conversely, building opportunities to fail unmarketable molecules earlier in the 
development process - fast-fail strategies - will shorten the time to first marketing authorization 
approval.  By focusing on the small minority of molecules that make it to market, development 
speed initiatives may sub-optimize the research and development process increasing costs and 
lowering productivity. 
 
 
 
